$850 million in Pakistan–China pharma pacts: vaccines, raw materials and devices
The July 2026 B2B conference ended with contracts and MoUs focused on local production of vaccines, pharmaceutical raw materials and medical devices.
In this article
The Pakistan-China Pharmaceutical & Healthcare B2B Investment Conference, held in Islamabad on 17–18 July 2026 and organised by SIFC, the health ministry and DRAP, ended with a set of agreements aimed at making more of Pakistan’s medicines — and their ingredients — at home.
What was signed
Digital Pakistan reported agreements worth roughly $850 million: 16 contracts worth $600 million and 80 MoUs worth $250 million, 18 of them on herbal medicines. INP-WealthPK reported slightly different totals (22 commercial agreements worth $629.5 million and 84 MoUs worth about $800 million); either way, the scale is significant.
Priority areas
- Vaccines — the health minister warned that vaccine import costs could reach $1.2 billion by 2030.
- Pharmaceutical raw materials — Pakistan imports about 90% of them.
- Medical devices.
- Other accords cover clinical trials, vocational training and technology transfer.
About 146 Chinese companies and more than 200 Pakistani firms took part, according to Digital Pakistan. Several Chinese executives said they expected implementation within two years.
What to watch
Analysts cautioned that turning MoUs into factories will need consistent policy, timely regulatory approvals and infrastructure. The test will be how many projects reach construction in 2027.
Contracts and MoUs are not the same
The headline totals mix two very different kinds of agreement. A commercial contract is a binding commitment to supply, buy or invest on stated terms. A memorandum of understanding (MoU) records an intention to work together; it is often the first step towards a project, but it does not commit either side to spend money. That is why the reported totals differ between sources and why analysts urged caution. The number to watch is not the value signed in July, but how many projects reach land acquisition, regulatory approval and construction.
Why the focus on raw materials and vaccines
Pakistan makes most of its finished medicines at home but depends on imports for the ingredients and for most vaccines. That leaves the country exposed to exchange-rate swings, freight disruptions and supply decisions made elsewhere. Local production of key raw materials and vaccines would reduce that exposure — but both are technically demanding:
- API and intermediate plants need chemical or fermentation expertise, reactors, solvent recovery, effluent treatment and strict GMP for active substances.
- Vaccine plants need aseptic manufacturing, biological expertise, cold chain and a regulator able to oversee them to international standards.
- Medical devices range from simple disposables to electronic equipment, with quality systems and testing to match.
This is where partnerships with experienced Chinese manufacturers are meant to help: technology transfer, training and shared investment can shorten the learning curve.
What makes these projects succeed
Experience from other countries suggests a few common conditions: a clear and stable incentive framework, predictable regulatory approval, reliable power, water and gas, access to industrial land, and a guaranteed market for at least the first years of production. Several of these are in government hands, which is why the conference was organised by SIFC together with the health ministry and DRAP. The coming months will show whether that coordination carries through to project approvals.
What local companies can do now
For Pakistani manufacturers and suppliers, the practical question is how to take part. Companies with land, licences or existing plants may be attractive partners for foreign investors looking for a quick start. Engineering firms, cleanroom builders, utility contractors and laboratories can position themselves for the construction and validation work that new plants will need. Distributors can offer market access for the products that eventually come out of the factories. Each of these roles starts with relationships — the kind built at industry events.
Where the openings are
| Area | Who could benefit |
|---|---|
| Raw-material plants | Reactor, utility and cleanroom suppliers; local partners |
| Vaccine facilities | Aseptic filling, cold chain and QC laboratories |
| Device units | Component makers, testing and regulatory services |
Chinese and Pakistani companies meet again at Pharma Asia 2026 — see the 45 Chinese exhibitors.
Sources
- Digital Pakistan, “Pakistan-China pharma summit seals $850m in investment pacts”, 20 July 2026
- INP-WealthPK, “Pakistan’s pharma industry faces value-addition test as export targets rise”, 2 September 2026
- Dental Tribune Pakistan, “Pakistan, China launch major pharma investment drive to boost local manufacturing”, 17 July 2026
